Medicine composition for treating malignant pleural effusion and preparation method thereof

Abstract

The invention discloses a medicine composition for treating malignant pleural effusion and a preparation method of the medicine composition. The medicine composition is prepared from the following raw materials by weight: 15-25 parts of rabdosia rubescens, 10-20 parts of curcuma wenyujin, 5-15 parts of brucea javanica, 5-15 parts of radix sophorae flavescentis, 8-12 parts of arisaema erubescens, 8-12 parts of poria cocos, 7-13 parts of fructus aurantii, 5-15 parts of glossy privet fruit, 12-18 parts of herba epimedii, 7-13 parts of konjak, 12-18 parts of rice sprout, 15-25 parts of oldenlandia, 15-25 parts of sculellaria barbata, 5-13 parts of paris polyphylla, 7-13 parts of centipede, and 2-10 parts of scabrous elephantfoot herb; the various materials are extracted with water or ethyl alcohol to prepare the medicine composition, the chemotherapy is conducted with the medicine composition at the same time, the excellent synergistic interaction effects are achieved, no effect of inhibiting the bone marrow is produced, the synthesis of RNA and the protein is also not affected, the medicine composition has a remarkable effect of inhibiting the adhesion of a vascular endothelial cell of a neoplastic cell nuclei, directly stimulates pleura to lead to adhesion and fibrosis, has the effects of strongly astringing and inhibiting the secretion of the pleura, is an effective medicine for treating the malignant pleural effusion, and has a huge clinical application prospect.

Description

technical field [0001] The invention relates to a medicine for treating thoracic diseases, in particular to a medicine composition for treating malignant pleural effusion and a preparation method thereof. Background technique [0002] Pleural effusion is one of the common clinical symptoms of pleural effusion, about 25% of which is malignant pleural effusion, mainly from lung cancer, followed by breast cancer, malignant lymphoma, mesothelioma, etc. The appearance of malignant pleural effusion indicates that the tumor has In the advanced stage, active and effective treatment for malignant pleural effusion should be taken while actively treating the primary tumor; pleural effusion caused by malignant tumor metastasis to the pleura or primary pleural tumor is malignant pleural effusion, malignant pleural effusion The formation of tumors is usually caused by the following factors: (1) tumor pleural metastasis increases pleural permeability; (2) tumor infiltration and accompanyin...

AI Technical Summary

Problems solved by technology

[0002] Pleural effusion is one of the common clinical symptoms of pleural effusion, about 25% of which is malignant pleural effusion, mainly from lung cancer, followed by breast cancer, malignant lymphoma, mesothelioma, etc. The appearance of malignant pleural effusion indicates that the tumor has In the advanced stage, active and effective treatment for malignant pleural effusion should be taken while actively treating the primary tumor; pleural effusion caused by malignant tumor metastasis to the pleura or primary pleural tumor is malignant pleural effusion, malignant pleural effusion The formation of tumors is usually caused by the following factors: (1) tumor pleural metastasis increases pleural permeability; (2) tumor infiltration and accompanying inflammation increase capillary permeability; (3) tumor thrombus blocks blood vessels and lymph tube, or combined with mediastinal lymph node metastasis, which hinders the return and absorption of pleural effusion; (4) atelectasis caused by tumor further reduces intrapleural pressure; (5) secondary base monoleukemia, etc.; local treatment of malignant pleural effusion The purpose is to rule out pleural effusion, relieve oppressive symptoms, alleviate patient pain, restore original lung function, and try to directly kill cancer cells or aseptic inflammatory adhesions in the pleural cavity. Different, most of the methods currently used are intrathoracic injection of cisplatin, elemene milk and Lierfan. As a broad-spectrum cancer drug, cisplatin is widely used in primary hospitals because of its definite curative effect and low price. It can directly kill cancer cells on the surface of the serosal cavity and in the effusion without liver activation, so it has been used as one of the first-choice drugs for intracavitary chemotherapy, but its severe gastrointestinal reactions bring certain pain and psychological burden to patients. In addition, it also has different degrees of bone marrow suppression, which often brings difficulties to the timely implementation of the next treatment; elemene milk is an effective anticancer drug extracted from the traditional Chinese medicine Curcuma, and its active ingredient, elemene, can inhibit tumor cells. growth and reproduction, and can directly act on the cell membrane to cause tumor cell rupture and death, so it has a good curative effect in the treatment of malignant serous cavity effusion, but it is often accompanied by adverse reactions such as fever and chest pain; Lierfan is derived from hemolysis It is a biological response modifier extracted from Streptococcus streptococci, which can directly kill tumor cells and regulate the patient's body to effectively inhibit and kill tumor cells. immune function, control the progression of malignant tumors, and require intrapleural perfusion; based on the above reasons, there is no effective, small side effect, and easy-to-use drug for the treatment of malignant pleural effusion, and it is urgent to carry out this Research and Discussion on Aspects

Images